- Home
- STRW vs SGMO Comparison
STRW vs SGMO Comparison
Compare STRW & SGMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STRW | SGMO |
|---|---|---|
| Founded | 2015 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 151.1M | 141.2M |
| IPO Year | 2019 | 2000 |
Fundamental Metrics
Financial Performance| Metric | STRW | SGMO |
|---|---|---|
| Price | $12.68 | $0.40 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $12.33 | $5.75 |
| AVG Volume (30 Days) | 30.7K | ★ 3.7M |
| Earning Date | 05-25-2026 | 05-11-2026 |
| Dividend Yield | ★ 4.98% | N/A |
| EPS Growth | 46.15 | ★ 66.89 |
| EPS | ★ 0.44 | N/A |
| Revenue | ★ $117,058,000.00 | $36,567,000.00 |
| Revenue This Year | $8.24 | $4.79 |
| Revenue Next Year | $5.16 | N/A |
| P/E Ratio | $29.23 | ★ N/A |
| Revenue Growth | 17.29 | ★ 88.60 |
| 52 Week Low | $8.70 | $0.35 |
| 52 Week High | $14.00 | $1.04 |
Technical Indicators
Market Signals| Indicator | STRW | SGMO |
|---|---|---|
| Relative Strength Index (RSI) | 50.59 | 48.07 |
| Support Level | $12.68 | $0.36 |
| Resistance Level | $13.65 | $0.56 |
| Average True Range (ATR) | 0.48 | 0.04 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 60.34 | 16.61 |
Price Performance
Historical ComparisonAbout STRW Strawberry Fields REIT Inc.
Strawberry Fields REIT Inc is a self-managed and self-administered company that specializes in the acquisition, ownership and triple-net leasing of skilled nursing facilities and other post-acute healthcare properties.
About SGMO Sangamo Therapeutics Inc.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.